| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net revenues | $61.16B+8.6% | $56.33B+3.7% | $54.32B-6.4% | $58.05B+3.3% | $56.20B+22.7% | $45.80B+37.7% | $33.27B+1.6% | $32.75B+16.1% | $28.22B |
| Cost of products sold | $18.20B+7.7% | $16.90B-17.2% | $20.41B+17.2% | $17.41B-0.2% | $17.45B+13.4% | $15.39B+106.8% | $7.44B-3.6% | $7.72B+9.6% | $7.04B |
| Selling, general and administrative | $14.01B-5.0% | $14.75B+14.6% | $12.87B-15.6% | $15.26B+23.6% | $12.35B+9.3% | $11.30B+62.8% | $6.94B-6.2% | $7.40B+17.5% | $6.29B |
| Research and development | $9.10B-28.9% | $12.79B+66.7% | $7.67B+17.9% | $6.51B-6.0% | $6.92B+8.5% | $6.38B-0.4% | $6.41B-38.0% | $10.33B+106.3% | $5.01B |
| Acquired IPR&D and milestones | $5.02B+81.9% | $2.76B+254.4% | $778.0M+11.6% | $697.0M-38.0% | $1.12B-18.3% | $1.38B+257.4% | $385.0M-9.2% | $424.0M+29.7% | $327.0M |
| Other operating income | -$241.0M-3342.9% | -$7.0M+96.1% | -$179.0M-419.6% | $56.0M-87.0% | $432.0M | $0+100.0% | -$890.0M-278.0% | $500.0M | $0 |
| Total operating costs and expenses | $46.09B-2.4% | $47.20B+13.6% | $41.56B+4.1% | $39.94B+4.3% | $38.27B+11.1% | $34.44B+69.8% | $20.28B-23.1% | $26.37B+41.2% | $18.67B |
| Operating earnings | $15.07B+65.0% | $9.14B-28.4% | $12.76B-29.6% | $18.12B+1.1% | $17.92B+57.7% | $11.36B-12.5% | $12.98B+103.4% | $6.38B-33.1% | $9.54B |
| Interest expense, net | $2.63B+21.6% | $2.16B+28.3% | $1.68B-17.6% | $2.04B-14.3% | $2.38B+4.6% | $2.28B+51.1% | $1.51B+31.9% | $1.14B+13.9% | $1.00B |
| Net foreign exchange loss | $58.0M+176.2% | $21.0M-85.6% | $146.0M-1.4% | $148.0M+190.2% | $51.0M-28.2% | $71.0M+69.0% | $42.0M+75.0% | $24.0M-93.1% | $348.0M |
| Other expense, net | $5.79B+78.8% | $3.24B-30.7% | $4.68B+91.1% | $2.45B-2.1% | $2.50B-55.5% | $5.61B+86.8% | $3.01B+16600.0% | $18.0M-96.1% | $466.0M |
| Earnings before income tax expense | $6.60B+77.5% | $3.72B-40.5% | $6.25B-53.6% | $13.48B+3.8% | $12.99B+282.3% | $3.40B-59.7% | $8.43B+62.1% | $5.20B | — |
| Income tax expense (benefit) | $2.36B+514.7% | -$570.0M-141.4% | $1.38B-15.6% | $1.63B+13.3% | $1.44B+217.6% | -$1.22B-325.0% | $544.0M+211.0% | -$490.0M-120.3% | $2.42B |
| Net earnings | $4.23B-1.2% | $4.29B-12.0% | $4.87B-58.9% | $11.85B+2.6% | $11.55B+149.9% | $4.62B-41.4% | $7.88B+38.6% | $5.69B+7.1% | $5.31B |
| Net earnings attributable to noncontrolling interest | $7.0M-12.5% | $8.0M-20.0% | $10.0M+11.1% | $9.0M+28.6% | $7.0M+16.7% | $6.0M | $0 | $0 | — |
| Net earnings attributable to AbbVie Inc. | $4.23B-1.2% | $4.28B-12.0% | $4.86B-58.9% | $11.84B+2.5% | $11.54B+150.0% | $4.62B-41.4% | $7.88B+38.6% | $5.69B+7.1% | $5.31B |
| Basic earnings per share (in dollars per share) | $2370000.00-1.3% | $2400000.00-12.1% | $2730000.00-58.9% | $6650000.00+2.6% | $6480000.00+137.4% | $2730000.00-48.5% | $5300000.00+44.4% | $3670000.00+10.9% | $3310000.00 |
| Diluted earnings per share (in dollars per share) | $2360000.00-1.3% | $2390000.00-12.1% | $2720000.00-59.0% | $6630000.00+2.8% | $6450000.00+137.1% | $2720000.00-48.5% | $5280000.00+44.3% | $3660000.00+10.9% | $3300000.00 |
| Weighted-average basic shares outstanding (in shares) | 1.77B+0.0% | 1.77B+0.1% | 1.77B-0.2% | 1.77B+0.1% | 1.77B+6.2% | 1.67B+12.6% | 1.48B-3.9% | 1.54B-3.4% | 1.60B |
| Weighted-average diluted shares outstanding (in shares) | 1.77B+0.0% | 1.77B+0.0% | 1.77B-0.3% | 1.78B+0.1% | 1.78B+6.2% | 1.67B+12.7% | 1.48B-4.0% | 1.55B-3.6% | 1.60B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.